AstraZeneca plc (LON:AZN)’s share price fell 0% during mid-day trading on Monday . The company traded as low as GBX 5,145.10 ($69.77) and last traded at GBX 5,153 ($69.88). 1,360,345 shares traded hands during mid-day trading, a decline of 22% from the average session volume of 1,740,000 shares. The stock had previously closed at GBX 5,153 ($69.88).
Several equities analysts have issued reports on the stock. UBS Group set a GBX 4,550 ($61.70) target price on shares of AstraZeneca and gave the company a “neutral” rating in a research note on Monday. Jefferies Group restated a “hold” rating and set a GBX 5,100 ($69.16) target price on shares of AstraZeneca in a research note on Monday, November 6th. Morgan Stanley set a GBX 4,700 ($63.74) target price on shares of AstraZeneca and gave the company a “neutral” rating in a research note on Friday, October 20th. Deutsche Bank restated a “buy” rating and set a GBX 5,600 ($75.94) target price on shares of AstraZeneca in a research note on Wednesday, October 11th. Finally, JPMorgan Chase & Co. set a GBX 4,500 ($61.03) target price on shares of AstraZeneca and gave the company a “neutral” rating in a research note on Wednesday, October 18th. Four equities research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the stock. AstraZeneca presently has a consensus rating of “Hold” and a consensus price target of GBX 5,200.82 ($70.53).
The company has a market cap of $65,150.00 and a price-to-earnings ratio of 2,501.46.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.